Open in App
  • U.S.
  • Election
  • Newsletter
  • targetedonc.com

    Second-line Treatment for RS-negative Lower-Risk MDS: Choosing Between EMA and Telomerase Inhibitor Options

    By Mikkael Sekeres, MD,

    2 days ago
    Comments / 0
    Add a Comment
    YOU MAY ALSO LIKE
    Most Popular newsMost Popular

    Comments / 0